Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact

Introducing RSVpreF vaccination for older adults in Sweden has the potential to reduce RSV-related hospitalizations, deaths, and healthcare costs. Findings support the implementation of RSV vaccination to older adults and at-risk individuals as a cost-effective and budget-saving strategy in the short term.